Weekly Recap | INNOVENT BIO +7.39%, closing in on record highsWeekly Review·1 day ago, 01:51 AM01801+1.19%
Innovent Biologics climbs 3% on mRNA cancer vaccine trial resultsHK Stock Market Update·Aug 19 at 08:42 PM01801+1.19%
M Stanley Raises INNOVENT BIO TP to HKD138.5 on Strong 1H Product RevenueAASTOCKS News·Aug 18 at 11:26 PM01801+1.19%
Forget the Hype, Innovent Biologics' $10.5B Pfizer Deal is the Real Power MoveGlobal Report·Aug 18 at 05:11 AM01801+1.19%
Spero Q2 FY26 net loss widens to $9.6 million; revenue posts no revenuePUBT·Aug 12 at 03:01 PMSPRO+0.83%01801+1.19%
Innovent Biologics schedules board meeting to review interim resultsPUBT·Aug 10 at 04:05 AM01801+1.19%
Innovent Biologics signs exclusive deal with Daiichi Sankyo to commercialize Vanflyta in ChinaPUBT·Aug 9 at 07:00 PM01801+1.19%4568
BOCOM International Holdings Company Sticks to Their Buy Rating for Innovent Biologics (IVBXF)Tip Ranks·Aug 7 at 12:55 AM01801+1.19%
G Sachs Raises INNOVENT BIO TP to HKD111.68 on Strong 1H Product Revenue GrowthAASTOCKS News·Aug 5 at 11:21 PM01801+1.19%
